GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · IEX Real-Time Price · USD
+0.070 (2.46%)
Jun 21, 2024, 4:00 PM EDT - Market closed

GT Biopharma Statistics

Total Valuation

GT Biopharma has a market cap or net worth of $6.30 million. The enterprise value is -$3.48 million.

Market Cap 6.30M
Enterprise Value -3.48M

Important Dates

The next estimated earnings date is Monday, August 5, 2024, before market open.

Earnings Date Aug 5, 2024
Ex-Dividend Date n/a

Share Statistics

GT Biopharma has 2.16 million shares outstanding. The number of shares has increased by 27.50% in one year.

Shares Outstanding 2.16M
Shares Change (YoY) +27.50%
Shares Change (QoQ) -0.05%
Owned by Insiders (%) 6.67%
Owned by Institutions (%) 15.67%
Float 1.20M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 1.19
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.01.

Current Ratio 2.15
Quick Ratio n/a
Debt / Equity 0.01
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -9,635.00

Financial Efficiency

Return on equity (ROE) is -111.50% and return on invested capital (ROIC) is -243.39%.

Return on Equity (ROE) -111.50%
Return on Assets (ROA) -66.10%
Return on Capital (ROIC) -243.39%
Revenue Per Employee n/a
Profits Per Employee -$4.82M
Employee Count 2
Asset Turnover n/a
Inventory Turnover n/a


Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -72.06% in the last 52 weeks. The beta is 0.62, so GT Biopharma's price volatility has been lower than the market average.

Beta (1Y) 0.62
52-Week Price Change -72.06%
50-Day Moving Average 3.56
200-Day Moving Average 5.69
Relative Strength Index (RSI) 42.29
Average Volume (20 Days) 115,695

Short Selling Information

The latest short interest is 36,013, so 1.67% of the outstanding shares have been sold short.

Short Interest 36,013
Short Previous Month 2,735
Short % of Shares Out 1.67%
Short % of Float 3.01%
Short Ratio (days to cover) 0.41

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -13.00M
Pretax Income -9.64M
Net Income -9.64M
EBIT -9.64M
Earnings Per Share (EPS) -$6.98
Full Income Statement

Balance Sheet

The company has $9.81 million in cash and $30,000 in debt, giving a net cash position of $9.78 million or $4.53 per share.

Cash & Cash Equivalents 9.81M
Total Debt 30,000
Net Cash 9.78M
Net Cash Per Share $4.53
Equity / Book Value 5.31M
Book Value Per Share 2.46
Working Capital 5.29M
Full Balance Sheet

Cash Flow

Operating Cash Flow -10.11M
Capital Expenditures n/a
Free Cash Flow -10.11M
FCF Per Share -$7.32
Full Cash Flow Statement


Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

GT Biopharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -27.50%
Shareholder Yield -27.50%
Earnings Yield -153.02%
FCF Yield -160.53%

Analyst Forecast

The average price target for GT Biopharma is $105.00, which is 3,495.89% higher than the current price. The consensus rating is "Buy".

Price Target $105.00
Price Target Difference 3,495.89%
Analyst Consensus Buy
Analyst Count 2
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on February 5, 2024. It was a reverse split with a ratio of 1:30.

Last Split Date Feb 5, 2024
Split Type Reverse
Split Ratio 1:30


Altman Z-Score n/a
Piotroski F-Score n/a